The Canopy Cancer Collective Clinical Registry Protocol Non-Interventional Data and Sample Collection Registry Protocol
Number of study sites 15 Study Design - Observational, registry Primary Objective To systematically collect and store comprehensive data on gastrointestinal cancer patients, encompassing both their past medical history and future clinical experiences, to address specific future research questions related to these malignancies, to establish and share best practices, and to support quality improvement initiatives focused on enhancing patient care and outcomes.
Secondary Objective(s) 1. Leverage the collective to increase access to molecular profile and biomarker (ctDNA) matched clinical trials across the treatment trajectory.
2\. Use real world data and patient reported outcomes to improve patient care throughout the treatment trajectory.
Research Procedure(s) Collection of clinical and outcome data and cataloging and facilitating access to physical biological specimens and their associated data for future research purposes.
Drugs/Devices used on Study None Study Population Patients with diagnosis of gastrointestinal (GI) cancers who seek care at one of the canopy centers and/or their affiliates Sample Size Up to 30000 patients in the prospective component
Up to 70000 subjects will be enrolled on the retrospective component Study Duration for Individual Participants Anticipated to be at least 1 year Study Specific Abbreviations AE: Adverse Event CEC: Clinical Events Committee CT: Computed Tomography iCCA: Intrahepatic cholangiocarcinoma MRI: Magnetic Resonance Imaging OS: Overall Survival PFS: Progression Free Survival
Must have reached the age of majority in the jurisdiction where enrolled (18 years; Alabama/Nebraska 19; Puerto Rico 21).
Deceased, or
Lost to follow-up ( >1 year lapse in contact since last visit).
Must have reached the age of majority in the jurisdiction where enrolled (18 years; Alabama/Nebraska 19; Puerto Rico 21).
None
This is a multicenter, retrospective and prospective study designed to build a database and a virtual biospecimen repository of patients with GI cancers.
Cohort
Other
Not listed
Number of participants enrolled in registry
Count of participants enrolled in the Canopy Cancer Collective GI cancer registry (prospective + retrospective).
Objective Response Rate (ORR)
For each line of therapy, best overall response where RECIST 1.1 is available.
Progression-Free Survival (PFS)
Time from start of each line of therapy to disease progression or death (as available).
Time to Selection of Next Therapy
Time from start of a line of therapy to initiation of subsequent therapy.
Molecular Testing Rate
Percent of participants undergoing germline and somatic tumor testing.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
